Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Proshares Trust (ZBIO) Total Current Liabilities (2023 - 2025)

Historic Total Current Liabilities for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to $52.4 million.

  • Zenas BioPharma's Total Current Liabilities rose 1914.68% to $52.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.4 million, marking a year-over-year increase of 1914.68%. This contributed to the annual value of $57.3 million for FY2024, which is 14633.24% up from last year.
  • Zenas BioPharma's Total Current Liabilities amounted to $52.4 million in Q3 2025, which was up 1914.68% from $53.2 million recorded in Q2 2025.
  • Zenas BioPharma's Total Current Liabilities' 5-year high stood at $57.3 million during Q4 2024, with a 5-year trough of $23.3 million in Q4 2023.
  • For the 3-year period, Zenas BioPharma's Total Current Liabilities averaged around $46.6 million, with its median value being $50.8 million (2025).
  • In the last 5 years, Zenas BioPharma's Total Current Liabilities soared by 14633.24% in 2024 and then surged by 1914.68% in 2025.
  • Zenas BioPharma's Total Current Liabilities (Quarter) stood at $23.3 million in 2023, then soared by 146.33% to $57.3 million in 2024, then decreased by 8.5% to $52.4 million in 2025.
  • Its Total Current Liabilities was $52.4 million in Q3 2025, compared to $53.2 million in Q2 2025 and $49.1 million in Q1 2025.